Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
- PMID: 11062477
- DOI: 10.1038/81664
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
Abstract
Proper serum phosphate concentrations are maintained by a complex and poorly understood process. Identification of genes responsible for inherited disorders involving disturbances in phosphate homeostasis may provide insight into the pathways that regulate phosphate balance. Several hereditary disorders of isolated phosphate wasting have been described, including X-linked hypophosphataemic rickets (XLH), hypophosphataemic bone disease (HBD), hereditary hypophosphataemic rickets with hypercalciuria (HHRH) and autosomal dominant hypophosphataemic rickets (ADHR). Inactivating mutations of the gene PHEX, encoding a member of the neutral endopeptidase family of proteins, are responsible for XLH (refs 6,7). ADHR (MIM 193100) is characterized by low serum phosphorus concentrations, rickets, osteomalacia, lower extremity deformities, short stature, bone pain and dental abscesses. Here we describe a positional cloning approach used to identify the ADHR gene which included the annotation of 37 genes within 4 Mb of genomic sequence. We identified missense mutations in a gene encoding a new member of the fibroblast growth factor (FGF) family, FGF23. These mutations in patients with ADHR represent the first mutations found in a human FGF gene.
Similar articles
-
FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E1-9. doi: 10.1152/ajpendo.00016.2003. Am J Physiol Endocrinol Metab. 2003. PMID: 12791601 Review.
-
FGF23 and disorders of phosphate homeostasis.Cytokine Growth Factor Rev. 2005 Apr;16(2):221-32. doi: 10.1016/j.cytogfr.2005.01.002. Epub 2005 Feb 5. Cytokine Growth Factor Rev. 2005. PMID: 15863037 Review.
-
Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets.Calcif Tissue Int. 2007 Dec;81(6):415-20. doi: 10.1007/s00223-007-9067-4. Epub 2007 Nov 29. Calcif Tissue Int. 2007. PMID: 18046499
-
FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.J Bone Miner Res. 2007 Apr;22(4):520-6. doi: 10.1359/jbmr.070107. J Bone Miner Res. 2007. PMID: 17227222
-
A familial disorder with low bone density and renal phosphate wasting.Eur J Intern Med. 2009 Sep;20(5):503-8. doi: 10.1016/j.ejim.2009.03.003. Epub 2009 Apr 17. Eur J Intern Med. 2009. PMID: 19712854
Cited by
-
Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children.Front Endocrinol (Lausanne). 2020 May 28;11:338. doi: 10.3389/fendo.2020.00338. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32547492 Free PMC article. Review.
-
FGF23, a novel muscle biomarker detected in the early stages of ALS.Sci Rep. 2021 Jun 8;11(1):12062. doi: 10.1038/s41598-021-91496-6. Sci Rep. 2021. PMID: 34103575 Free PMC article.
-
FGF-23 and secondary hyperparathyroidism in chronic kidney disease.Nat Rev Nephrol. 2013 Nov;9(11):641-9. doi: 10.1038/nrneph.2013.147. Epub 2013 Jul 23. Nat Rev Nephrol. 2013. PMID: 23877588 Review.
-
Fibroblast growth factor 23 inhibition attenuates steroid-induced osteonecrosis of the femoral head through pyroptosis.Sci Rep. 2024 Jul 15;14(1):16270. doi: 10.1038/s41598-024-66799-z. Sci Rep. 2024. PMID: 39009650 Free PMC article.
-
Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging.Nutrients. 2020 Sep 30;12(10):3001. doi: 10.3390/nu12103001. Nutrients. 2020. PMID: 33007883 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous